N. Keegan, S. Furney, J. Walshe, G. Gullo, J. Kennedy, K. Bulger, J. McCaffrey, C. Kelly, K. Egan, P. O'Donovan, A. Hernando, A. Teiserskiene, I. Parker, A. Farrelly, A. Carr, G. Calzaferri, R. McDermott, M. Keane, L. Grogan, O. Breathnach, P. Morris, S. Toomey, B. Hennessy
{"title":"P1-19-24: copanlisib联合曲妥珠单抗治疗复发或转移性her2阳性乳腺癌“PantHER”的Ib期试验","authors":"N. Keegan, S. Furney, J. Walshe, G. Gullo, J. Kennedy, K. Bulger, J. McCaffrey, C. Kelly, K. Egan, P. O'Donovan, A. Hernando, A. Teiserskiene, I. Parker, A. Farrelly, A. Carr, G. Calzaferri, R. McDermott, M. Keane, L. Grogan, O. Breathnach, P. Morris, S. Toomey, B. Hennessy","doi":"10.1158/1538-7445.sabcs19-p1-19-24","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”\",\"authors\":\"N. Keegan, S. Furney, J. Walshe, G. Gullo, J. Kennedy, K. Bulger, J. McCaffrey, C. Kelly, K. Egan, P. O'Donovan, A. Hernando, A. Teiserskiene, I. Parker, A. Farrelly, A. Carr, G. Calzaferri, R. McDermott, M. Keane, L. Grogan, O. Breathnach, P. Morris, S. Toomey, B. Hennessy\",\"doi\":\"10.1158/1538-7445.sabcs19-p1-19-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20307,\"journal\":{\"name\":\"Poster Session Abstracts\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Session Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.sabcs19-p1-19-24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Session Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.sabcs19-p1-19-24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P1-19-24: A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”